Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Tuesday, June 26, 2012
Dynavax (DVAX): FDA Accepts Hepatitis B Vaccine Biologics License Application
The company anticipates submitting a European Marketing Authorization Application (MAA) for HEPLISAV in the third quarter of 2012.